



## CATHERINE A. SAZDANOFF

Board member, consultant and mentor with extensive experience in global industry: corporate development strategy and M&A, business development, expansion and restructuring, legal, compliance and enterprise risk management.

### PROFESSIONAL EXPERIENCE:

#### **VASCUGEN, INC.**

2021-present

Independent Director of Board

- Private stem-cell R&D company.

#### **STRATA ONCOLOGY, INC.**

2016-present

Chief Business Development, Legal and Compliance Officer (2021-present)

Previous roles: Strategy/ Business Advisor, Chief Compliance Officer, Chief Business Officer

- Private precision oncology company.

#### **SAZDANOFF CONSULTING LLC**

2015 – present

President & CEO

- Healthcare business advisory services, including for: Vascugen (joined board); Fujifilm Cellular Dynamics Inc.; mProve Health (acquired 2017); women's health specialty pharma; Canadian generics company; drug repurposing pharma; novel pain management startup; dementia informatics platform startup.

#### **MERIDIAN BIOSCIENCE, INC. (NASDAQ: VIVO)**

2015-2023

Independent Director of Board; Chair, Nominating & Governance Committee; member, Compensation and Audit Committees

- Global diagnostics and life sciences company, acquired by Korean operating and investment consortium.

#### **INMED PHARMACEUTICALS, INC. (NASDAQ: INM)**

2019-2022

Independent Director of Board; Chair, Nominating & Governance and member, Audit and Compensation Committees

- Developing rare cannabinoid-based Rx treatments for high unmet-need diseases; proprietary bio-synthesis platform.

#### **UNIVERSITY OF CHICAGO**

2018-2021

- Lecturer, Business of Biotechnology professional certificate/ graduate credit program.
- Courses: Managing Operations and Board Relations; IP Law.

#### **TAKEDA PHARMACEUTICALS**

2006 - 2015

Global corporate roles (VP Global Business Development, VP Corporate Development, VP Head of Corporate Projects, VP Global Licensing, Senior Director BD)

- Built and led corporate M&A team: strategy, target evaluation, banker/ deal source management, all aspects of transactions.

- Lead negotiator/ overall co-lead on acquisition of Nycomed S.A. (US\$ 13.7 B, 2011; >30% increase revenue & EPS, footprint >60 countries), and of Millennium Pharmaceuticals (US\$ 8.8 B, 2008; oncology revenue, pipeline and capabilities).
- Led R&D BD team (CNS, CV/ metabolic, immunology, respiratory, vaccines, GI, renal): strategy, M&A/ collaboration evaluations and transactions, global integration, partnership governance.
- Led WW restructuring and enterprise risk management initiatives. Exceeded target for US\$ 500 million recurring savings.

#### **ABBOTT LABORATORIES**

1984 - 2006

Global corporate and pharmaceutical division roles (Division VP/ Senior Counsel, Office of Ethics & Compliance; Senior Counsel, International Licensing & Acquisitions and Global Litigation; Director, Business Development/ Strategic Licensing; Senior Product Manager)

- Co-lead lawyer on US\$ 7 billion acquisition of Knoll Pharmaceuticals from BASF, adding multiple assets including mega-blockbuster Humira®.
- Lead lawyer and co-lead negotiator on multiple M&A and licensing deals, adding >US\$ 300 MM in revenue, pipeline products and technology rights.
- Increased market share for Biaxin® pediatric antibiotic by 50% in 6 months.
- Led pharmaceutical business development function; closed multiple licensing deals.
- Senior legal advisor for Europe and Canada.
- Roles of increasing responsibility for litigation worldwide (IP, antitrust, contracts, product liability, labor, regulatory, shareholder claims and mass tort litigation); 10-0 trial record.
- Legal advisor to pharmaceutical life cycle management team, extending exclusivity of selected products and adding US \$500 MM additional revenue.
- Successfully resolved infant formula antitrust matters, by trial (civil US \$9 billion claim; Puerto Rico government bid-rigging claim), settlement (FTC) and closure without charges (Canadian Competition Bureau). Favorably settled US federal fraud and abuse investigation in enteral nutrition business, including negotiated Corporate Integrity Agreement.
- Re-launched and globalized compliance program; designed and managed WW operations (~50 staff); directed strategic planning, risk assessments and internal investigations.

**ISHAM, LINCOLN & BEALE**, Chicago IL  
Litigation associate.

1981 - 1983

#### **EDUCATION:**

J.D., Northwestern University School of Law  
B.A. (English with honors), University of Notre Dame

#### **PROFESSIONAL AFFILIATIONS**

*Current:* DirectWomen; Mentor at MATTER Chicago; Cristo Rey St. Martin College Prep School Jobs Committee; Private Directors Association.

*Former:* NACD; Women Corporate Directors; Executive-in-Residence and External Advisory Board member for Rosalind Franklin University Innovation and Research Park; Practicing Law Institute Advanced Licensing course faculty.